BXQ-350 nanovesicles target and identify tumors. In preclinical mouse and rat models,
our nanovesicles specifically seek and exclusively localize within tumors, even
metastasized and spontaneous tumors.
Bexion’s BXQ-350 targets what appear to be ubiquitous phosphatidylserine (PS) lipids
on tumor cells and the blood vessels that feed them, resulting in efficacy being
observed across a wide variety of cancer types. Selectivity is achieved by activation
based on local pH. Because the key biologic in BXQ-350 is a lysosomal protein, it
is inactive at normal physiological pH’s, becoming active only in the acidic microenvironments
inherent in solid tumors, including brain tumors.
Spontaneous glioblastoma in a mouse made visible by labeling with BXQ-350-CVM.
Video by: X. Qi, K. LaSance, L. Lemen, Z. Chu (University of Cincinnati), B. Kaur, C-H. Kwon (Ohio State University)
Left: BXQ-350 with a fluorescent marker, CVM goes directly to pancreatic cancer.
Right: The same tumor, but imaged through luminescence (i.e., tumor manipulated to glow with luciferase).